-
公开(公告)号:US20200246372A1
公开(公告)日:2020-08-06
申请号:US16854978
申请日:2020-04-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Eran HORNSTEIN , Irit REICHENSTEIN , Alon CHEN
IPC: A61K31/7105 , A61P25/00 , A61K45/06 , C12N15/113
Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.
-
公开(公告)号:US10723770B2
公开(公告)日:2020-07-28
申请号:US16726290
申请日:2019-12-24
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Ada Yonath , Zohar Eyal , Donna Matzov , Haim Rozenberg , Ella Zimmerman , Anat Bashan
IPC: C07K14/31 , C07H17/08 , C07D263/20 , C07D211/54 , G16B15/00 , G16B30/00 , G16C20/50 , G16B35/00 , G16C20/60
Abstract: A composition-of-matter comprising a crystallized form of a large ribosomal (50S) subunit of a pathogenic bacterium, and the atomic coordinates of the three-dimensional structure thereof are provided herein, as well as methods for crystallizing the same, and using the atomic coordinates of the same to design de novo ligands with high specificity thereto.
-
公开(公告)号:US20200206283A1
公开(公告)日:2020-07-02
申请号:US16683332
申请日:2019-11-14
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Eran SEGAL , Eran ELINAV
IPC: A61K35/747 , A61K35/745 , A61K35/744 , A61K35/741 , A61P3/08
Abstract: A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.
-
684.
公开(公告)号:US10668094B2
公开(公告)日:2020-06-02
申请号:US15745441
申请日:2016-07-19
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Steven J. D. Karlish , Adriana Katz , Daniel M. Tal , Arie Marcovich
Abstract: Provided herein are alpha2-selective Na,K-ATPase inhibitors and prodrugs thereof, characterized by having a cyclic moiety attached to a digoxin or digitoxin derivative, as well as uses thereof in lowering intraocular pressure and in treating glaucoma and heart conditions.
-
公开(公告)号:US20200094069A1
公开(公告)日:2020-03-26
申请号:US16397515
申请日:2019-04-29
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Avigdor SCHERZ , Alexander BRANDIS , Ohad MAZOR , Yoram SALOMON , Hugo SCHEER
IPC: A61N5/06 , C07F15/00 , C07F13/00 , C07F3/06 , C07F3/02 , C07F1/08 , A61K41/00 , A61F9/00 , C07F15/04 , A61K49/00 , A61K31/40
Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.
-
公开(公告)号:US20200080207A1
公开(公告)日:2020-03-12
申请号:US16684889
申请日:2019-11-15
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor: Ron NAAMAN , Claudio FONTANESI , Wilbert MTANGI
Abstract: An electrode is presented for use in an oxidation process. The electrode comprises a substrate having an electrically conductive surface carrying a chiral system. The chiral system is configured for controlling spin of electrons transferred between the substrate and electrolyte during the oxidation process.
-
公开(公告)号:US20200032370A1
公开(公告)日:2020-01-30
申请号:US16591644
申请日:2019-10-03
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor: Igor LUBOMIRSKY , Valery Kaplan
Abstract: A method for recovery of platinum group metals from a spent catalyst is described. The method includes crushing the spent catalyst to obtain a catalyst particulate material including particles having a predetermined grain size. The method includes subjecting the catalyst particulate material to a chlorinating treatment in the reaction zone at a predetermined temperature for a predetermined time period by putting the catalyst particulate material in contact with the chlorine containing gas. The method also includes applying an electromagnetic field to the chlorine-containing gas in the reaction zone to provide ionization of chlorine; thereby to cause a chemical reaction between platinum group metals and chlorine ions and provide a volatile platinum group metal-containing chloride product in the reaction zone. Following this, the volatile platinum group metal-containing chloride product is cooled to convert the product into solid phase platinum group metal-containing materials.
-
公开(公告)号:US10545144B2
公开(公告)日:2020-01-28
申请号:US15108889
申请日:2014-12-31
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor: Irun R. Cohen , Eytan Domany , Noam Shental , Ittai Fattal
IPC: G01N33/564 , C12Q1/6883
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.
-
公开(公告)号:US10533028B2
公开(公告)日:2020-01-14
申请号:US15508114
申请日:2015-09-03
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor: David Milstein , Peng Hu , Eran Fogler , Jai Anand Garg Narayana Rao
IPC: C07F15/00 , C07C29/149 , C07C213/00 , C07C227/02 , C07C231/08 , C07C231/10 , B01J31/24 , C07C67/40 , C07C249/02 , C07D207/16 , C07D241/08
Abstract: The present invention relates to novel Ruthenium complexes of formulae A1-A4 and their use, inter alia, for (1) dehydrogenative coupling of alcohols to esters; (2) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones), or polyesters); (3) preparing amides from alcohols and amines—(including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or polymerization of amino alcohols and/or forming cyclic dipeptides from p-aminoalcohols; (4) hydrogenation of amides (including cyclic dipeptides, polypeptides and polyamides) to alcohols and amines; (5) hydrogenation of organic carbonates (including polycarbonates) to alcohols or hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (6) dehydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water and a base to form carboxylic acids; and (10) preparation of amino acids or their salts by coupling of amino alcohols with water and a base. The present, invention further relates to the use of certain known Ruthenium complexes for the preparation of amino acids or their salts from amino alcohols.
-
690.
公开(公告)号:US10519237B2
公开(公告)日:2019-12-31
申请号:US15261945
申请日:2016-09-10
Applicant: Yeda Research and Development Co. Ltd
Inventor: Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K39/00
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
-
-
-
-
-
-
-
-